Gadobenate dimeglumine (Gd-BOPTA): An overview

Investigative Radiology

Volumn 33, Issue 11, 1998, Pages 798-809

  Kirchin, Miles A ^a   Pirovano, Gianpaolo P ^a   Spinazzi, Alberto ^a  

^a Bracco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL;

CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0032470985     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199811000-00003     Document Type: Review

References (76)

1. Jackels SC. Enhancement agents for magnetic resonance imaging: Fundamentals. In: Swanson DP, Chilton HM, Thrall JH, eds. Pharmaceuticals in medical imaging. New York: Macmillan Publishing Co. Inc., 1990.
2. Lauterbur PC. Image formation by induced local interactions: Examples employing NMR. Nature 1973;242:190-191.
3. Hinshaw WS, Bottomley PA, Holland GN. Radiographic thin-section image of the human wrist by nuclear magnetic resonance. Nature 1977;270:722-723.
4. Andrew ER, Bottomley PA, Hinshaw WS, Holand GN, Moore WS, Simaroj C. NMR images by the multiple sensitive point method: Application to larger biological systems. Phys Med Biol 1977;22: 971-974.
5. Damadian R, Goldsmith M, Minkoff L. NMR in cancer. XVI: FONAR image of the live human body. Physiol Chem Phys 1977;9:97-100.
6. Lauterbur PC, Mendonca-Dias MH, Rudin AM. Augmentation of tissue water proton spin-lattice relaxation rates by the in vivo addition of paramagnetic ions. In: Dutton PL, eds. Frontiers of Biological Energetics. New York. NY: Academic Press. 1978.
7. Carr DH, Brown J, Bydder GM, et al. Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours. Lancet 1984;3:484-486.
8. Carr DH, Brown J, Leung A, Pennock JM. Iron and gadolinium chelates as contrast agents in NMR imaging: Preliminary studies. J Comput Assist Tomogr 1984;8:385-389.
9. Weinmann HJ. Characteristics of Gd-DTPA dimeglumine. In: Felix R, Heshiki A, Hosten N, Hricak H, eds. Magnevist monograph. Oxford: Blackwell Scientific Publications. 1994.
10. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents Invest Radiol 1992;27:S2-S6.
11. Watson AD. Theory and mechanisms of contrast-enhancing agents. In: Higgins CB, Hricak H, Helms CA, eds. Magnetic resonance imaging in the body. New York: NY: Raven Press, 1992.
12. de Haën C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 1993;3:179-186.
13. Vittadini G, Felder E, Musu C, Tirone P. Pre-clinical profile of Gd-BOPTA: A liver-specific MRI contrast agent. Invest Radiol 1990;25:S59-S60.
14. Davies A, de Haën C. Gadobenic acid dimeglumine salt. Drugs of the Future 1991:16(11):1001-1003.
15. Banci L, Bertini I, Luchinat C. Nuclear and electron relaxation. Weinheim, Germany: VCH Verlagsgesellschaft mbH, 1991.
16. Spinazzi A, Davies A, Villa A, Campani R, Meloni G, Cavagna F. Current status and future perspectives of research for new MR contrast media. Radiol Med 1997;93(1):36-45.
17. Cavagna FM, Marzola P, Daprà M, et al. Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts. Invest Radiol 1994;29: S50-S53.
18. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. Invest Radiol 1997;32:780-796.
19. Giovagnoni A, Paci E. Liver III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). MRI Clinics of North America 1996;4:61-72.
20. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging: Interrelations between pharmacokinetics and imaging. Invest Radiol 1993;28:753-761.
21. Vogl TJ Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J. MultiHance - A new contrast agent for MR imaging: Preliminary Evaluation in Healthy Volunteers. AJR Am J Roentgenol 1992;157:887-892.
22. Spinazzi A, Lorusso V, Pirovano GP, Kirchin M. Safety, tolerability, biodistribution, and MR enhancement of the liver with Gd-BOPTA: Results of clinical pharmacology and pilot imaging studies in non-patient and patient volunteers. Acad Radiol. In press.
23. Rosati G, Pirovano G, Spinazzi A. Interim results of phase II clinical testine of gadobenate dimeglumine. Invest Radiol 1994;29:S183-S185.
24. Niendorf HP, Alhassan A, Balzer Th, Clauß W, Cornelius I. Safety and risk of gadolinium-DTPA: Extended clinical experience after more than 5,000,000 applications. In: Felix R, Heshiki A, Hosten N, Hricak H, eds. Magnevist monograph. Oxford: Blackwell Scientific Publications, 1994.
25. Runge VM, Bradley WG, Brant-Zawadski MN, et al. Clinical safety and efficacy of gadoteridol:a study in 411 patients with suspected intracranial and spinal disease. Radiology 1991;181:701-709.
26. Runge VM, Parker JR. Worldwide clinical safety assessment of gadoteridol injection: An update. European Radiology 1997;7:S243-S245.
27. Lambrecht LJ, Davies BE, McCloud S, Parker JR, Swan SK. Safety and pharmacokinetics of gadobenate dimeglumine in subjects with renal impairment. Clin Pharmacol Therapeut 1998;63:229. Abstract.
28. de Haën C, Lorusso V, Luzzani F, Tirone P. Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 1995;2:232-238.
29. de Haën C, Lorusso V, Tirone P. Hepatic transport of gadobenate dimeglumine in TR - rats. Acad Radiol 1996;3:S452-S454.
30. Bonnemain B, Neiss AC, Doucet D, Beauté S, Meyer. Gd-DOTA: Chemistry, toxicity, and clinical results. In: Ferrucci JT, Stark DD, eds. Liver imaging: Current trends and new techniques. Boston: Andover Medical Publishers Inc., 1990.
31. Schima W, Mukerjee A, Saini S. Contrast-enhanced MR imaging. Clin Radiol 1996;51:235-244.
32. Cavagna F, Tirone P, Felder E, de Haën C. Hepatobiliary contrast agents for MRI. In: Ferrucci JT, Stark DD, eds. Liver imaging: Current trends and new techniques. Boston: Andover Medical Publishers Inc., 1990.
33. Cavagna F, Tirone P, Felder E, de Haën C. Gd-BOPTA/Dimeg: A new hepatobiliary contrast agent for magnetic resonance imaging. In: Rinck PA, Muller RN, eds. New developments in contrast agent research. Blonay, Switzerland: European Magnetic Resonance Forum, 1991.
34. Spinazzi A, Lorusso V, Pirovano GP, Taroni P, Kirchin M, Davies A. MultiHance clinical pharmacology: Biodistribution and MR enhancement of the liver. Acad Radiol 1998;5:S86-S89.
35. Marzola P, Maggioni F, Vicinanza E, Daprà M, Cavagna FM. Evaluation of the hepatocyte: Specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model. J Magn Reson Imaging 1997;7:147-152.
36. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183:59-64.
37. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: Dose, safety aspects, and pulse sequence. Radiology 1996;199:177-183.
38. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics and MR imaging. Radiology 1995;195:785-792.
39. Yuh WTC, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. Am J Neuroradiol AJN 1994;15:1037-1051.
40. 1-weighted spin-echo images with use of magnetization transfer. Radiology 1994;190: 553-559.
41. Hossman KA. Haemodynamic and metabolic disturbances in peritumoral edema. In: Johansson BB, Owman C, Widner H, eds. Pathophysiology of the blood-brain barrier. London: Elsevier Science Publishers, 1990.
42. Kuroiwa T, Ting P, Martinez H, Klatzo I. The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral occlusion. Acta Neuropathol (Berl) 1985;68:122-129.
43. Schmidt-Kastner R, Szymas J, Hossman KA. Immunohistochemical study of glial reaction and serum-protein extravasation in relation to neuronal damage in rat hyppocampus after ischemia. Neuroscience 1990;38:527-540.
44. Hossman KA, Hürter T, Oschilies U. The effect of dexamethasone on serum protein extravasation and edema development in experimental brain tunour of cat. Acta Neuropathol 1983;60:223-231.
45. Jenkins BG, Brouillet E, Chen YCI, et al. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996;16:450-461.
46. Caramia F, Huang Z, Hamberg LM, et al. Mismatch between cerebral blood volume and How index during transient focal ischemia studied with MRI and Gd-BOPTA. Magn Res Imag 1998;16:97-103.
47. Lauffer RB. Hepatobiliary agents for MRI: Rationale and preliminary evaluation. In: Ferrucci JT, Stark DD, eds. Liver imaging: Current trends and new techniques. Boston: Andover Medical Publishers Inc., 1990.
48. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA): Preliminary results of phase II clinical application. Radiology 1997;203:513-520.
49. Kreft BP, Tanimoto A, Stark DD, et al. Enhancement of tumor-liver contrast-to-noise ratio with gadobenate dimeglumine in MR imaging of rats. J Magn Reson Imaging 1993;3:41-49.
50. Brasch RC. New directions in the development of MR Imaging contrast media. Radiology 1992;183:1-11.
51. Saini S. Contrast-enhanced MR imaging of the liver. Radiology 1992; 182:12-14.
52. Hamm B, Taupitz M. Use of contrast agents in the detection and differentiation of focal liver lesions by MR imaging: Gd-DTPA. Mn-DPDP and iron oxide. In: Balzer T, Hamm B, Niendorf H-P, eds. Contrast agents in liver imaging. Dordrecht: Kluwer Academic Publishers. 1995.
53. Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: A multiinstitutional study of appearance of T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994; 192:14:401-406.
54. Mitchell DG, Saini S, Weinreb J, et al. Hepatic metastases and cavernous hemangiomas: Distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994;193:49-57.
55. Powers C, Ros PR, Stoupis C, Johnson WK, Segel KH. Primary MR Liver neoplasms: Imaging with pathologic correlation. Radio-Graphics 1994;14:459-482.
56. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: Characterisation with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994;190:417-423.
57. Mahfouz AE, Hamm B, Wolf KJ. Peripheral washout: A sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 1994;190:49-52.
58. Nakamura H, Murakami T, Ishida T, et al. 3DFT-FISP MRI with gadopentetate dimeglumine in differential diagnosis of small liver tumors. J Comput Assist Tomogr 1994;18:49-54.
59. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: Improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 1997;202:677-682.
60. Hamm B, Bassi AM, Grazioli L, et al. MultiHance-enhanced dynamic and delayed MR imaging in the detection and characterization of focal liver lesions. Proceedings of The International Society for Magnetic Resonance in Medicine 1997:67. Abstract.
61. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: Characterization with nonenhanced and dynamic contrast-material-enhanced MR imaging. Radiology 1994;190:417-423.
62. Bernardino ME, Young SW, Lee JKT, Weinreb JC. Hepatic MR imaging with Mn-DPDP: Safety, image quality and sensitivity. Radiology 1992;183:53-58.
63. Teslascan (mangafodipir trisodium) injection. Oslo. Norway: Nycomed, 1997. US Package Insert.
64. Rummeny E, Ehrenheim C, Gehl HB, et al. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Invest Radiol 1991;26:S142-S145.
65. Schima W, Petersein J, Hahn PF, Harisinghani M, Halpern E, Saini S. Contrast-enhanced MR imaging of the liver: Comparison between Gd-BOPTA and mangafodipir. J Magn Reson Imaging 1997;7: 130-135.
66. Ferrucci JT. Ferrite particles: Rationale and clinical results. In: Ferrucci JT, Stark DD, eds. Liver imaging: Current trends and new techniques. Boston: Andover Medical Publishers Inc., 1990.
67. Marchai G, Van Hecke P, Demaerel P, Decrop E, Baert AL. Iron oxide: High field MRI clinical results. In: Ferrucci JT, Stark DD, eds. Liver imaging: Current trends and new techniques. Boston: Andover Medical Publishers Inc., 1990.
68. Runge VM. Future directions in magnetic resonance contrast media. Top Magn Reson Imaging 1991;3:85-97.
69. 131I-albumin in dog heart: Lung preparations. Acta Pyhiol Scand 1964;62:209-217.
70. Judd RM, Levy BI. Effects of barium-induced cardiac contraction on large- and small-vessel intramyocardial blood volume. Circ Res 1991;68:217-225.
71. 1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus Gd-DTPA on inversion recovery EPI. Magn Res Med 1997;37:448-456.
72. Saeed M, Wendland MF, Sakuma H, et al. Coronary artery stenosis: Detection with contrast-enhanced MR imaging in dogs. Radiology 1995;196:79-84.
73. Cherryman GR, Tranter J, Keal R, et al. Prospective comparison of contrast-enhanced MRI with thallium 201 SPECT and 2D echocardiography in the localization of acute myocardial infarction. Proceedings of The International Society for Magnetic Resonance in Medicine 1998:899. Abstract.
74. Caramia F, Foley MT, Moore J, et al. Use of Gd-BOPTA/Dimeg in peripheral magnetic resonance angiography. Proceedings of The International Society for Magnetic Resonance in Medicine 1996: 1252. Abstract.
75. Cavagna FM, Maggioni F, Daprà M, Castelli PM, Imperatori LG. Gadobenate Improves strongly vessel conspicuity over gadopentetate in first-pass USTE 3D-TOF MRA. Proceedings of 14th annual meeting of The European Society for Magnetic Resonance in Medicine and Biology 1997:26. Abstract.
76. Knopp MV, Schoenberg SO, Rehm C, et al. Comparison of the efficacy of Gd-BOPTA and Gd-DTPA for MR angiography: A phase I pilot study. Proceedings of The International Society for Magnetic Resonance in Medicine 1998:174. Abstract.